BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination8.6.2026 16:16:00 CEST | Press release
RAAQ Extraordinary General Meeting Scheduled for June 25, 2026 IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced today that the registration statement on Form F-4 (the “Registration Statement”), relating to their previously announced business combination, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608520188/en/ IQM Radiance quantum computer The extraordinary general meeting of RAAQ’s shareholders in connection with the proposed business combination (the “Extraordinary General Meeting”) will be held on June 25, 2026. The proxy statement/prospectus relating to the Extraordinary General Meeting was mailed to RAAQ’s shareholders of record
Monster Hunter Wilds: Ascendance to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Monster Hunter: World, released in 2018, surpassed 30 million units as Capcom looks to expand its global user base – Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Wilds: Ascendance, a massive expansion for Monster Hunter Wilds, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608183725/en/ Monster Hunter Wilds Ascendance key art Monster Hunter Wilds: Ascendance is a massive expansion (paid content) for Monster Hunter Wilds, which was released in February 2025. As a continuation of the main game’s story, the expansion will further deepen the gameplay experience with new content including new quest ranks, locales, additional monsters and expanded weapon actions through new gameplay features. The company is currently developing the title for release in 2027. Capcom is also developing Monster Hunter Wilds for Nintendo Switch™ 2 in addition to the existing platforms. Furthe
Resident Evil Veronica to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Capcom aims to further enhance the IP’s value by remaking a popular title of the series – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Veronica, the latest title in the Resident Evil series, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608994346/en/ Resident Evil Veronica key art The Resident Evil franchise features survival horror games in which players utilize a variety of weapons and other items to survive terrifying situations. Supported by a passionate global fanbase, cumulative game sales since the first title in this flagship series debuted in 1996 exceed 201 million* units. Resident Evil Veronica is a remake of the original Resident Evil Code: Veronica, released in the year 2000. While preserving the appeal of the original, Capcom is developing the 2027 release as the latest installment of the Resident Evil series, with a reimagined story and high-quality g
Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization8.6.2026 15:00:00 CEST | Press release
Ulf Wiinberg appointed to Board of DirectorsWilliam “Bill” MacKenzie hired as Senior Vice President – Finance Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance. Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company’s development and commercialization strategy. Mr. Wiinberg’s experience includes serving as CEO of X-Vax Technology, Inc. from 2017 until 2024 and prior to that, he was CEO of Lundbeck from 2008 until 2014. From 2002 to 2008, he was a member of Wyeth’s Management Committee and during this time, he was Worldwide President of Wyeth Consumer Healthcare from 2002 to 2005, and President of Europe/Middle East/Africa until 2008, when Wyeth was acquired by Pfizer. Ulf serves as a d
Xylem Expands Long-Term Water Partnership with Dow8.6.2026 14:00:00 CEST | Press release
Agreement to design, build and operate advanced water solution Project to advance integrated water reuse capability, significantly reducing freshwater demand Xylem (NYSE: XYL), a leading global water technology company, today announced a landmark agreement with Dow (NYSE: DOW) to design, build and operate advanced water systems at its large-scale industrial complex in Fort Saskatchewan, Alberta, Canada. The agreement expands Xylem’s long-standing collaboration with Dow, supporting the increased operations tied to Dow’s Path2Zero project. Under the agreement, Xylem will deliver a full end-to-end solution that includes engineering, system design, and long-term operation. The project is designed to support reliable, high-quality water supply, treatment, and reuse across the site. The system is expected to be operational by August 2028. “This agreement represents a major milestone for Xylem,” said Rodney Aulick, EVP and President, Water Solutions and Services at Xylem. “It reflects the str
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom